QI-019A
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for QI-019A, covering 2026-02-24 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. [EARLY_Phase 1]